UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003512
Receipt number R000004256
Scientific Title Phase II study of combination chemotherapy with mitomycin and methotrexate for triple negative breast cancer
Date of disclosure of the study information 2010/04/25
Last modified on 2013/04/22 12:41:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of combination chemotherapy with mitomycin and methotrexate for triple negative breast cancer

Acronym

MM-TN trial

Scientific Title

Phase II study of combination chemotherapy with mitomycin and methotrexate for triple negative breast cancer

Scientific Title:Acronym

MM-TN trial

Region

Japan


Condition

Condition

Breast Cancer

Classification by specialty

Medicine in general Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Efficacy and safety of combination chemotherapy with mitomycin and methotrexate for triple negative breast cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Response rate by combination chemotherapy with mitomycin and methotrexate for triple negative breast cancer

Key secondary outcomes

Metastatic breast cancer: progression free survival, time to treatment failure, overall survival, adverse events
Locally advanced disease: pathological response rate, pathological complete response rate, clinical response rate,
breast conserving rate, disappearance rate of axillary node metastasis, distant-metastasis free survival, disease free survival, overall survival, adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Metastatic breast cancer: more than 4 cycles of mitomycin + methotrexate (MM), up to 6 times of mitomycin
Locally advanced breast cancer: 4 cycles of mitomycin + methotrexate (MM) followed by 4 cycles of FEC100. Then, surgery will be performed. Add weekly paclitaxel after surgery when axillary nodes was positive or pathological response was grade 0, 1.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

Histological confirmed breast cancer
Tumor size 3cm and more in stage IIIA, IIIB, IIIC. Stage IV or metastatic breast cancer
Triple negative; ER<10%, PgR<10%, HER2 negative (IHC 0,1 or FISH<2.0)
Age below 70
PS;0 or 1
Life expectancy; 6 months and more
WBC;4,000/mm3 and more or ANC;2,000/mm3 and more
Platelet 100,000/mm3 and more
Hemoglobin; 9 g/dl and more
AST,ALT; twice of an upper limit of normal value and less
Total bilirubin; 1.5 mg/dl and less
Creatinine; an upper limit of normal value and less
ECG within normal limit
Given written consent

Key exclusion criteria

Non invasive or microinvasive breast cancer
Previously treated with chemotherapy, hormone therapy or radiotherapy
Serious complication (infection, cardiac disease, pulmonary fibrosis interstitial pneumonitis, bleeding)
Hepatitis type B and its carrier
Pregnant, nursing or willing to be pregnant
Inadequate to entry judged by investigators

Target sample size

70


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshinori Ito

Organization

Cancer Institute Hospital, Japanese Foundation for Cancer Research

Division name

Department of Medical Oncology, Breast Cancer Center

Zip code


Address

3-8-31, Ariake, Koto-ku, Tokyo, 135-8550 Japan

TEL

03-3520-0111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yoshinori Ito

Organization

Cancer Institute Hospital, Japanese Foundation for Cancer Research

Division name

Department of Medical Oncology, Breast Cancer Center

Zip code


Address

3-8-31, Ariake, Koto-ku, Tokyo, 135-8550 Japan

TEL

03-3520-0111

Homepage URL


Email



Sponsor or person

Institute

Cancer Institute Hospital, Japanese Foundation for Cancer Research

Institute

Department

Personal name



Funding Source

Organization

Department of Medical Oncology, Cancer Institute Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 04 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 09 Month 29 Day

Date of IRB


Anticipated trial start date

2009 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 04 Month 20 Day

Last modified on

2013 Year 04 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004256


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name